My ePortfolio Register   

Promising partners for check-point immunotherapy for HCC?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.01.17
Views: 989

Dr Stephen Chan - The Chinese University of Hong Kong, Hong Kong

Dr Chan speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about predisposing factors of developing hepatocellular carcinoma, and how they might be tackled before cancer develops.

He describes how vaccines and anti-viral therapies have limited tumourigenic hepatitis infections, and how screening for alpha-fetoprotein or interleukin 10 can provide actionable biomarkers.

With regards to immunotherapeutic targets, Dr Chan considers how OX40, VEGF targeting and T cell therapy can improve response in combination with PD-1 checkpoint therapy, 

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence